Free Trial

Lexicon Pharmaceuticals (LXRX) Competitors

Lexicon Pharmaceuticals logo
$0.87 -0.03 (-3.13%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$0.89 +0.02 (+2.09%)
As of 07/7/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LXRX vs. CLDX, INVA, DVAX, MNKD, OPK, NVAX, GERN, RGLS, MYGN, and ZBIO

Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

Lexicon Pharmaceuticals vs. Its Competitors

Celldex Therapeutics (NASDAQ:CLDX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

Celldex Therapeutics has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$7.02M198.38-$157.86M-$2.70-7.77
Lexicon Pharmaceuticals$31.21M10.11-$200.40M-$0.51-1.71

Celldex Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 4.4% of Celldex Therapeutics shares are held by company insiders. Comparatively, 13.9% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Celldex Therapeutics. MarketBeat recorded 2 mentions for Lexicon Pharmaceuticals and 1 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.16 beat Lexicon Pharmaceuticals' score of 0.59 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celldex Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lexicon Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Celldex Therapeutics presently has a consensus target price of $50.11, suggesting a potential upside of 138.85%. Lexicon Pharmaceuticals has a consensus target price of $3.67, suggesting a potential upside of 320.10%. Given Lexicon Pharmaceuticals' higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.89
Lexicon Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

Lexicon Pharmaceuticals has a net margin of -568.04% compared to Celldex Therapeutics' net margin of -2,366.07%. Celldex Therapeutics' return on equity of -23.46% beat Lexicon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Celldex Therapeutics-2,366.07% -23.46% -22.35%
Lexicon Pharmaceuticals -568.04%-103.16%-54.95%

Summary

Celldex Therapeutics and Lexicon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Lexicon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LXRX vs. The Competition

MetricLexicon PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$325.70M$2.91B$5.52B$9.02B
Dividend YieldN/A2.44%5.24%4.07%
P/E Ratio-1.7120.4427.2220.04
Price / Sales10.11181.20380.3292.37
Price / CashN/A41.7026.2128.59
Price / Book2.187.397.945.55
Net Income-$200.40M-$55.04M$3.17B$248.49M
7 Day Performance-1.28%2.51%1.81%4.87%
1 Month Performance13.35%-0.21%1.28%6.63%
1 Year Performance-45.45%3.41%33.57%20.38%

Lexicon Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LXRX
Lexicon Pharmaceuticals
2.4726 of 5 stars
$0.87
-3.1%
$3.67
+320.1%
-47.7%$325.70M$31.21M-1.71140
CLDX
Celldex Therapeutics
3.0538 of 5 stars
$19.81
-2.4%
$50.11
+153.0%
-40.9%$1.31B$7.02M-7.34150
INVA
Innoviva
3.8525 of 5 stars
$20.01
+0.3%
$55.00
+174.9%
+15.6%$1.26B$358.71M-19.81100
DVAX
Dynavax Technologies
4.3732 of 5 stars
$10.01
+1.0%
$24.00
+139.8%
-8.4%$1.20B$277.25M-19.25350
MNKD
MannKind
2.5173 of 5 stars
$3.68
-2.1%
$10.33
+180.8%
-31.0%$1.12B$297.60M36.80400Negative News
OPK
OPKO Health
4.2186 of 5 stars
$1.32
-0.4%
$2.75
+109.1%
+6.3%$1.04B$713.10M-18.782,997
NVAX
Novavax
4.4691 of 5 stars
$6.40
+0.5%
$17.00
+165.6%
-44.5%$1.04B$682.16M2.421,990
GERN
Geron
2.8548 of 5 stars
$1.39
-7.0%
$5.06
+265.5%
-69.8%$882.13M$76.99M-6.5970Gap Down
RGLS
Regulus Therapeutics
1.5535 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830
MYGN
Myriad Genetics
4.1209 of 5 stars
$5.32
+1.3%
$14.38
+170.4%
-78.8%$490.40M$837.60M-4.752,700
ZBIO
Zenas BioPharma
1.1945 of 5 stars
$9.64
+0.6%
$36.67
+280.4%
N/A$403.28M$15M-2.72N/A

Related Companies and Tools


This page (NASDAQ:LXRX) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners